alendronate / Generic mfg. - LARVOL DELTA

ANTIRESORPTIVE TREATMENT OF OSTEOPOROSIS IN PATIENTS WITH SYSTEMIC SCLEROSIS: DO ORALLY ADMINISTERED DRUGS WORK (EULAR 2025) - "Antiresorptive therapies included alendronate (n=17), zoledronate (n=7), denosumab (n=11), risedronate (n=2), and ibandronate (n=1). Antiresorptive therapy appears effective and safe in patients with SSc. Subgroup analysis suggests that parenteral therapies may be more effective, with denosumab showing the most consistent improvements in axial BMD. Notably, both oral and parenteral antiresorptive drugs were well-tolerated, as no adverse events were observed."

Clinical • Gastrointestinal Disorder • Immunology • Osteoporosis • Rheumatology • Scleroderma • Systemic Sclerosis

MULTI-TARGET THERAPY IN PREVENTION OF STEROID-INDUCED OSTEONECROSIS: A RANDOMIZED CONTROLLED CLINICAL TRIAL. PRELIMINARY REPORT (EULAR 2025) - "The intervention group was administered a daily dosage of atorvastatin (40 mg), Aspirin (80 mg), and vitamin E (400 mg), along with a weekly dose of alendronate (70 mg). The initial findings suggest that a multi-target therapy could potentially prove effective in both preventing and mitigating steroid-induced osteonecrosis. While the multi-target therapy demonstrated a trend toward reducing the incidence of steroid-induced osteonecrosis, this observation did not reach statistical significance."

Clinical • Metabolic Disorders

ANALYSIS OF BONE TURNOVER MARKERS IN PATIENTS TREATED WITH ROMOSOZUMAB IN CLINICAL PRACTICE (EULAR 2025) - "Regarding prior treatment, 8 patients had received bisphosphonates (BF) (4 zoledronate, 4 alendronate), 4 teriparatide, 3 denosumab (Dmab), and 2 raloxifene. In real-world clinical practice, the prior therapeutic sequence influences both BTM and BMD responses to Rmab. Patients previously treated with BF achieved superior BMD increases compared to those transitioning from teriparatide or Dmab. The BTM behavior suggests a potential “rebound” effect in patients transitioning from Dmab to Rmab."

Clinical • Musculoskeletal Diseases • Orthopedics • Otorhinolaryngology • Respiratory Diseases • Sinusitis

ROMOSOZUMAB IN PATIENTS WITH OSTEOPOROSIS: SAFETY AND EFFICACY ANALYSIS IN CLINICAL PRACTICE (EULAR 2025) - "Following romosozumab, the most frequently used therapies were denosumab (44.4%), risedronate (27.8%), zoledronic acid (13.9%), alendronate (5.6%), and teriparatide (2.8%). Romosozumab therapy represents a safe bone-forming treatment option for elderly patients with established classic cardiovascular risk factors. An increase in bone formation markers and a reduction in bone resorption markers were observed in blood tests, along with an improvement in bone mineral density as measured by densitometry. The most commonly used treatment following romosozumab was denosumab, followed by bisphosphonates."

Clinical • Congestive Heart Failure • Diabetes • Dyslipidemia • Genetic Disorders • Heart Failure • Hypertension • Metabolic Disorders • Musculoskeletal Diseases • Musculoskeletal Pain • Non-melanoma Skin Cancer • Osteoporosis • Pain • Parotid Gland Cancer • Rheumatology • Skin Cancer • Solid Tumor

SUBTROCHANTERIC FEMORAL FRACTURES (ATYPICAL OR NOT) AND PREVIOUS TREATMENT WITH BISPHOSPHONATE (EULAR 2025) - "In patients with subtrochanteric fracture, 6 had received alendronate, 1 risedronate and 1 denosumab. Subtrocanteric femoral fractures are associated with higher BMI and the use of bisphosphonate or denosumab. Atypical fracture is rare, accounting only 3% of subtrocanteric type."

Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

A MULTICENTRIC CROSS SECTIONAL STUDY EVALUATING THE BONE HEALTH IN YOUNG PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (EULAR 2025) - "A total of 36 (16.7%) patients were exposed to bisphosphonate therapy including Alendronate(17), Ibandronate(4), Risedronate(6), Zoledronate(9), and 13, 3, 4, and 8 patients were detected with low BMD, respectively. This is the first study evaluating the prevalence of low BMD in young patients with SLE in India. Low BMD was observed in 28.12% of patients. In SLE, nephritis and higher cumulative dose of glucocorticoids may contribute to elevated fracture risk."

Clinical • Observational data • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Musculoskeletal Diseases • Nephrology • Orthopedics • Osteoporosis • Rheumatology • Systemic Lupus Erythematosus

Teriparatide in the real world - efficacy and safety (EULAR 2025) - "Alendronate was the most common first-line bisphosphonate...After Teriparatide, 40 patients (74%) transitioned to Denosumab, 7 (13%) began Zoledronic acid, 5 passed away, and 2 were lost to follow-up... Our study demonstrates real world use of Teriparatide in a multi-ethnic diverse setting. It shows that Teriparatide is used predominantly in complex, multi-morbid older individuals with several prior fractures. Despite that, Teriparatide remains effective for a wide range of individuals including those with inflammatory arthritis and/or concurrent steroid use."

Clinical • Real-world • Real-world evidence • Immunology • Inflammatory Arthritis • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Paget's Disease of Bone: Clinical and Epidemiological Profiling of a Portuguese Cohort at a Tertiary Center (EULAR 2025) - "First line treatment was with zoledronate in 60 (75.0%) patients, pamidronate in 8 (10.0%) patients, alendronate in 4 (5.0%) patients, calcitonin in 3 (3.8%) patients, risedronate in 1 (1.3%) patient and denosumab in 1 (1.3%) patient. To the best of our knowledge, this study describes the largest Portuguese cohort of PDB patients. A high prevalence of this disease in rural areas and a high biochemical remission rate after treatment were noted. Patients treated with a non-zoledronate drug as first line therapy had a higher rate of retreatment than patients treated with zoledronate as first line therapy (HR 10.10)."

Clinical • Orthopedics • Rare Diseases

RATES OF CONCURRENT BMD RESPONSES AT THE LUMBAR SPINE AND TOTAL HIP IN PATIENTS RECEIVING ROMOSOZUMAB OR TERIPARATIDE FOLLOWING BISPHOSPHONATE THERAPY: A POST HOC ANALYSIS OF THE RANDOMISED PHASE 3 STRUCTURE TRIAL (EULAR 2025) - P3 | " In STRUCTURE, postmenopausal women with osteoporosis who had received an oral BP for ≥3 years (mean [SD] duration: 6.2 [2.9] years) and alendronate for the year prior to screening were randomised to subcutaneous Romo 210 mg monthly (QM) or TPTD 20 µg daily for 12 months [3]. A substantially greater proportion of previously BP-treated postmenopausal women receiving Romo had >3%/>6% concurrent improvements in BMD at both the LS and TH within 12 months compared with TPTD. These data add to the evidence indicating superiority of Romo in attaining BMD improvements within 12 months, across key skeletal sites in patients with osteoporosis."

Clinical • P3 data • Retrospective data • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Buffered soluble alendronate treatment preventing rebound following denosumab discontinuation in erosive hand OA: a randomized trial (EULAR 2025) - "A 48-week buffered soluble alendronate regimen more effectively prevents bone loss following denosumab withdrawal in erosive HOA patients compared to a 24-week regimen, supporting a safe denosumab discontinuation protocol. Exploratory outcomes suggest alendronate does not arrest radiographic progression nor deterioration of hand pain."

Clinical • Immunology • Osteoarthritis • Osteoporosis • Pain • Rheumatology

Concerns and questions regarding "Focusing on spinal stenosis: emerging discoveries concerning Alendronate-induced risks and genetic drug targets". (PubMed, J Orthop Surg Res) - No abstract available

Journal • Musculoskeletal Diseases • Orthopedics

Bisphosphonates with high bone-resorption-capacity promote osteonecrosis of the jaw development after tooth extraction in mice. (PubMed, J Bone Miner Metab) - "Administration of BPs with high osteoclastogenesis inhibitory potential, such as zoledronate, increases risk of ONJ development after tooth extraction more than treatment with other agents tested, even at equivalent dosage."

Journal • Preclinical • Osteoporosis • Rheumatology

Evaluation of the fracture prevention effects of teriparatide and alendronate in patients with frailty: a sub-analysis of the Japanese osteoporosis intervention trial-05. (PubMed, J Bone Miner Metab) - "In patients with physical frailty, TPTD reduced vertebral fractures significantly more than ALN. However, in cases with cognitive impairment, the results of the JOINT-05 study may not necessarily apply. Assessing the presence of dyslipidemia and cognitive decline may be useful for predicting adherence-related discontinuation."

Journal • Alzheimer's Disease • Cognitive Disorders • Dyslipidemia • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Capsaicin counteracts dexamethasone-induced osteoporosis and metabolic disturbances in rats: role of AMPK/SIRT1/β-catenin/RUNX2 pathway. (PubMed, J Mol Histol) - "For this reason, this study compared the anti-resorptive properties of capsaicin with alendronate, the conventional treatment for osteoporosis, using a rat model of osteoporosis induced by dexamethasone (Dexa)...Additionally, capsaicin improved bone architecture and effectively mitigated Dexa's detrimental metabolic impact on blood glucose and lipid profile. By upregulating the AMPK/SIRT1/β-catenin/RUNX2 pathway, capsaicin exhibits dose-dependent bone-stimulant effects in a dexamethasone-induced osteoporosis model in rats."

IO biomarker • Journal • Preclinical • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • BAX • BCL2 • RUNX2 • TRPV1

Surgical periodontal therapy for the management of intrabony/furcation defects with and without topically delivered Alendronate - a systematic review and meta-analysis. (PubMed, Evid Based Dent) - "The topical application of ALN has been shown to enhance the effectiveness of surgical periodontal therapy by reducing the PPD and DD and increasing the CAL; however, the certainty of evidence remains very low to low."

Journal • Retrospective data

Bone-targeted and redox-responsive polymeric nanomicelles based on hyaluronic acid. (PubMed, Int J Pharm) - "To achieve this goal, polymeric nanomicelles composed of hyaluronic acid (HA), alendronate (ALN), dithiodipropionic acid (DPA, containing disulfide bond -SS-), and hexadecanol (C16) were prepared for curcumin (CUR) delivery...Reb blood hemolysis assay and cytotoxicity tests on fibroblast cells showed that these polymeric nanomicelles were blood-compatible and non-toxic. Additionally, cytotoxicity tests on MDA-MB-231 cell lines confirmed the nanomicelles' ability to enhance the cytotoxic efficiency of the encapsulated drug."

Journal • Hematological Disorders • Oncology

Safety profile and risk factors associated with incadronate disodium treatment in breast cancer patients with bone metastases: A retrospective analysis. (ASCO 2025) - "Incadronate disodium demonstrates a favorable safety profile in managing bone metastases in breast cancer patients. Prolonged treatment duration and lower hemoglobin levels were identified as key risk factors, underscoring the need for proactive dental health management and tailored therapeutic strategies to minimize adverse outcomes."

Retrospective data • Breast Cancer • Endocrine Disorders • Nephrology • Oncology • Renal Disease • Solid Tumor

Adaptation of mitochondrial bioenergetics to coenzyme Q deficiency in human endothelial cells after chronic exposure to bisphosphonates. (PubMed, Sci Rep) - "Compared with the mitochondria of control cells, those of endothelial cells treated with 5 µM alendronate or 1 µM zoledronate presented a significant 45-50% decrease in total mtCoQ pool, loss of reduced (mtCoQH2) antioxidant mtCoQ pool, and elevated mitochondrial antioxidant protein superoxide dismutase 2 (SOD2) and uncoupling protein 2 (UCP2) levels. Despite the N-BP-induced decrease in a-heme levels, maximal CIV activity remained unaffected in endothelial mitochondria. These findings highlight the role of N-BPs in disrupting mtCoQ redox homeostasis and associated bioenergetic functions in endothelial mitochondria."

Journal • Cardiovascular • Metabolic Disorders • Orthopedics • SOD2

Bone Mineral Density and Bone Quality Trends in a Child on Steroid Therapy Who Developed a Vertebral Fracture: A Case Report. (PubMed, Cureus) - "Two months into treatment, she developed thoracic vertebral fractures (VFs) and was diagnosed with GIOP, prompting the initiation of oral alendronate sodium hydrate...No further fractures were observed after the cessation of antiresorptive treatment, which was guided by serial monitoring of BMD and BTMs. This case underscores the association of VFs with a decline in bone formation markers and elevations in bone resorption and matrix-related markers and demonstrates how BTMs reflecting bone quality can aid in determining the optimal duration of antiresorptive treatment in pediatric patients with GIOP."

Journal • Musculoskeletal Diseases • Nephrology • Orthopedics • Osteoporosis • Pediatrics • Rheumatology • TRAP

Challenges in Endocrine Function Testing During Clinical Cancer Drug Trials: False Positives Due to Heterophilic Antibodies (ENDO 2025) - "She was referred to the Endocrinology Department for osteoporosis management, and after evaluation, she was treated with Denosumab and cholecalciferol...Two months after switching to alendronate, PTH was measured at 1171 pg/mL...Following the initiation of osteoporosis treatment, the patient participated in a clinical trial to assess the safety and efficacy of Oregovomab in combination with Paclitaxel, Carboplatin, and Bevacizumab... Heterophilic antibodies have been recognized for a long time, but caution is needed as mouse-derived antibodies are still used in early-stage research. These antibodies can cross-react with non-homologous antigens, interfere with immunoassays, and lead to inaccurate test results.*. .*"

Clinical • Endocrine Disorders • Oncology • Osteoporosis • Ovarian Cancer • Pituitary Gland Carcinoma • Rheumatology • Solid Tumor

Romosozumab Effects on Bone Density, Muscle Mass, and Spine Surgery Outcomes (clinicaltrials.gov) - P2 | N=36 | Not yet recruiting | Sponsor: Nitin Agarwal

New P2 trial • Orthopedics • Osteoporosis • Rheumatology

FABP4 inhibition suppresses bone resorption and protects against postmenopausal osteoporosis in ovariectomized mice. (PubMed, Nat Commun) - "Notably, bone-targeted delivery of BMS309403 achieves comparable efficacy to alendronate. In this work, we demonstrate that FABP4 is a critical mediator in PMOP and that its inhibition offers a promising therapeutic strategy."

Journal • Preclinical • Inflammation • Metabolic Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • FABP4 • NFATC1

Tailoring diblock copolymers for efficient siPLK1 delivery and enhanced gene therapy of orthotopic osteosarcoma. (PubMed, J Mater Chem B) - "The shielding PEG block, further modified with an alendronate sodium (AS) moiety, enabled OS-targeted delivery of siPLK1. The designed copolymer achieved 83.9% in vitro PLK1 gene silencing, outperforming Lipo3000 (49.3%), and demonstrated superior anti-tumor (74.6% inhibition rate) and anti-metastasis effects in a highly metastatic orthotopic 143B OS model."

Journal • Gene Therapies • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • PLK1

Impact of Frailty and Other Factors as Estimated by HU to Predict Response to Anabolic Bone Medications. (PubMed, J Clin Med) - "Medications were grouped as anabolic (teriparatide, romosozumab) and antiresorptive (denosumab, alendronate) therapies. Our study highlights that male sex and higher pre-treatment HU were independently associated with lower odds of HU improvement, while medication type was not a significant predictor. Additionally, anabolic agents offered superior improvement relative to antiresorptive therapies."

Journal • Orthopedics • Osteoporosis • Rheumatology

The effect of Jintiange capsules on pain in patients with primary osteoporosis: a systematic review and meta-analysis. (PubMed, BMC Musculoskelet Disord) - "In terms of relieving pain, improving BMD, improving activity function, and improving gait and preventing fracture, JTG is a good choice for patients with osteoporosis (OP)."

Clinical • Journal • Retrospective data • Review • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Pain • Rheumatology